Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations

Vermess, Michael; Jl, Doppman; Sugarbaker, P H; Fisher, R I; O'Leary, Timothy J.; Dc, Chatterji; Grimes, George J.; Adamson, RH; Willis, Monte S.; Edwards, BK

doi:10.2214/ajr.138.6.1063

Cited by 41 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ethiodized Oil Emulsion 13 (EOE-13) is a relatively new lipoid intravenous contrast agent developed at the NIH to improve the accuracy of CT studies of the liver and spleen (76). Miller et al compared the sensitivity of EOE-13 enhanced CT (EOE-CT) and scintigraphy with findings at laparotomy in 49 patients at risk for liver metastasis from primary or recurrent malignancies (77).…”

Section: Detection Of Colorectai Cancer Metastases After Curative Resmentioning

confidence: 99%

Clinical perspective of human colorectal cancer metastasis

1984

View full text Add to dashboard Cite

Death from colorectal cancer frequently results from manifestations of recurrent local or metastatic disease following initial 'curative' therapy. Presently, the attempted curative treatment of recurrent colorectal cancer lays in the hands of the surgeon. This paper reviews the natural history of surgically treated large bowel cancer and summarizes published and National Cancer Institute experience with the surgical therapy of recurrent disease. A schema with rationale is offered for follow-up of the patient following 'curative' bowel resection. The treatment of recurrent disease incorporating the use of CEA initiated second-look laparotomy is advocated. Hepatic and pulmonary resections for metastatic disease are accepted as important therapeutic endeavours, and are discussed in some detail. It is concluded that of all patients diagnosed as having large bowel cancer, roughly 70% are resectable for cure at time of presentation, and 45% will indeed be cured by primary resection. Of the 25% who fail primary therapy, approximately 20% (5% of all colorectal cancer patients) can be cured by local re-resection or hepatic or pulmonary resection.

show abstract

Section: Detection Of Colorectai Cancer Metastases After Curative Resmentioning

confidence: 99%

Clinical perspective of human colorectal cancer metastasis

1984

View full text Add to dashboard Cite

show abstract

“…Liver-specific contrast media (CM) for both CT and MR imaging are currently under development, and preliminary clinical studies have shown increased sensitivity and specificity (7,11,13,22,31).…”

mentioning

confidence: 99%

CT and MR Imaging of the Liver Using Liver-Specific Contrast Media

Leander

Månsson

Ege³

et al. 1996

Acta Radiol

View full text Add to dashboard Cite

show abstract

“…Dose-dependent subjective AE showed similarities to the human response of phagocytising bacteria or viruses. It is known from previous studies that particular contrast agents can elicit such AE [9] and hence were not classified as unexpected. The changes in the differential counting of leucocytes seen among the lower doses might reflect a change in distribution between circulating and marginating leucocytes.…”

Section: Discussionmentioning

confidence: 99%

“…Foreign particles in the blood are taken up by macrophages in the reticuloendothelial system (RES), in liver constituted by the Kupffer cells. In experimental and clinical studies liver-specific contrast media using particles, i. e. emulsions and liposomes, have been investigated [6,7,8,9]. Since liver metastases do not contain Kupffer cells, the contrast of normal liver tissue to focal lesions is increased.…”

Section: Introductionmentioning

confidence: 99%

A new liposomal liver-specific contrast agent for CT: first human phase-I clinical trial assessing efficacy and safety

Leander¹,

Höglund

Børseth³

et al. 2001

European Radiology

View full text Add to dashboard Cite

In this first clinical trial liposome-encapsulated iodixanol, CT particles (CTP) were studied. The aims of the present trial were to assess the efficacy of CTP in CT and to determine the safety of different doses of CTP. A total of 47 healthy volunteers were enrolled in the present study. The CTP was administered at doses 10, 30, 70 and 100 mg encapsulated I/kg bw. Efficacy was assessed using single-slice CT of the abdomen and evaluated by dose-response attenuation curves over time in liver, spleen, and abdominal vessels. Safety was assessed by blood tests, clinical examinations and recording of subjective adverse events (AE). The attenuations in liver tissue increased with the dose and maximal values above baseline were 20, 39 and 45 HU at the doses 30, 70 and 100 mg encapsulated I/kg bw, respectively. Maximal increases were seen 12.5 min after contrast administration. As for liver, the attenuations in spleen increased with the dose, but higher attenuations were obtained. In early images clinically significant enhancement was seen in abdominal vessels. Mild and moderate subjective AE were encountered at the doses 70 and 100 mg encapsulated I/kg bw. The CTP is efficacious in enhancing hepatic and splenic tissues and in early imaging of abdominal vessels. Adverse event precludes a clinical use of CTP in the current formulation.

show abstract

Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations

Cited by 41 publications

References 0 publications

Clinical perspective of human colorectal cancer metastasis

Clinical perspective of human colorectal cancer metastasis

CT and MR Imaging of the Liver Using Liver-Specific Contrast Media

A new liposomal liver-specific contrast agent for CT: first human phase-I clinical trial assessing efficacy and safety

Contact Info

Product

Resources

About